Article Figures & Data
Figures
- FIGURE 1.
Schematic representation of study procedures over time. IMP = investigational medicinal product.
- FIGURE 2.
Normal biodistribution of [68Ga]Ga-NOTA-anti-CD206-sdAb. (A) Anterior maximum intensity projections of patient 1 at 11 min (left), 90 min (center), and 150 min (right) after injection. (B) Axial PET/CT fusion image at 90 min after injection, showing uptake in liver, spleen, kidneys, and adrenals (arrows). No tracer uptake is visible in lung lesion of this patient.
- FIGURE 3.
Relative organ uptake over time. Data are decay-corrected to time of injection and shown as mean ± SD in 6 patients. %IA = percentage injected activity; pi = after injection.
- FIGURE 4.
Time–activity curve for total blood volume and total plasma volume, expressed as percentage injected activity (%IA). Data are presented as mean ± SD of 7 patients.
- FIGURE 5.
Uptake of [68Ga]Ga-NOTA-anti-CD206-sdAb in patient 1 (A–C) and patient 2 (D–F), both with non–small cell lung carcinoma and residual lesion in lung region during treatment. (A and D) Uptake in lung lesion (arrow) on PET/CT (top) and PET (bottom) images 90 min after injection. Coronal PET images show lesional uptake, indicated by ellipsoid in left lung, for [68Ga]Ga-NOTA-anti-CD206-sdAb (B) and [18F]FDG performed 15 wk after study participation (C) of patient 1, who showed long-term disease remission. Coronal PET images show lesional uptake, indicated by ellipsoid in left lung of patient 2, for [68Ga]Ga-NOTA-anti-CD206-sdAb (E) and [18F]FDG performed 11 wk later (F). This patient showed disease progression on these [18F]FDG PET/CT images.
Tables
Patient no. Age (y) Sex Cancer type ECOG score Current therapy Previous lines 1 63 Male NSCLC 0 Pembrolizumab 0 2 69 Male NSCLC 1 Durvalumab 1 3 64 Male NSCLC 1 Pembrolizumab 0 4 54 Male NSCLC 1 Nivolumab 3 5 56 Male NSCLC 0 Atezolizumab 2 6 66 Male Atypical carcinoid 1 Watchful waiting 1 7 55 Male Renal cell carcinoma 1 Nivolumab 3 ECOG = Eastern Cooperative Oncology Group; NSCLC = non–small cell lung carcinoma.
Organ Male organ dose Female organ dose Kidneys 0.241 ± 0.048 0.263 ± 0.0517 Liver 0.135 ± 0.0138 0.181 ± 0.0188 Spleen 0.119 ± 0.0339 0.145 ± 0.0415 Urinary bladder wall 0.0477 ± 0.0118 0.0634 ± 0.0161 Adrenals 0.0475 ± 0.0129 0.0561 ± 0.0150 Thyroid 0.0287 ± 0.0207 0.0346 ± 0.0250 Red bone marrow 0.0267 ± 0.0038 0.0260 ± 0.0035 Heart wall 0.0244 ± 0.0244 0.0288 ± 0.0059 Osteogenic cells 0.0214 ± 0.0025 0.0288 ± 0.0034 Effective dose, ICRP 103 0.0219 ± 0.0010 0.0269 ± 0.0012 Effective dose, ICRP 60 0.0217 ± 0.0012 0.0271 ± 0.0015 ICRP = International Commission on Radiological Protection.
Organ doses are in milligrays per megabecquerel. Effective doses are in millisieverts per megabecquerel.
Patient no. Lesion-of-inclusion location Injected activity (MBq) SUVpeak SUVmax Disease progression after injection* Time to progression after injection (mo) Time to death after injection (mo) 1 Left upper lobe 174 1.0 1.2 No — Alive* 2 Left upper lobe 184 3.2 4.0 Yes 2 12 3 Mediastinal adenopathy 181 1.0 1.1 No — Alive* 4 Left upper lobe 236 NA 2.3 Yes 1 6 6 L3 vertebra 1.8 2.0 Yes 9 20 Scapula 185 1.8 2.4 Subpleural left 2.0 2.4 7 Left iliac wing 183 0.7 1.0 No — Alive* — = no disease progression; * = patient still alive; NA = not applicable.
Progression is based on PERCIST criteria or, if no [18F]FDG PET/CT data were available, on iRECIST criteria (38,39).
Supplemental Data
Files in this Data Supplement:
